197 related articles for article (PubMed ID: 36028933)
1. Recent Updates on the Anticancer Activity of Quinoxaline Hybrids (Jan. 2017-Jan. 2022).
Feng LS; Gao C; Liu FW; Wang XP; Zhang ZL
Curr Top Med Chem; 2022; 22(17):1426-1441. PubMed ID: 36028933
[TBL] [Abstract][Full Text] [Related]
2. Recent updates on 1,2,3-, 1,2,4-, and 1,3,5-triazine hybrids (2017-present): The anticancer activity, structure-activity relationships, and mechanisms of action.
Dong G; Jiang Y; Zhang F; Zhu F; Liu J; Xu Z
Arch Pharm (Weinheim); 2023 Mar; 356(3):e2200479. PubMed ID: 36372519
[TBL] [Abstract][Full Text] [Related]
3. Moxifloxacin-isatin Hybrids Tethered by 1,2,3-triazole and their Anticancer Activities.
Yang M; Liu H; Zhang Y; Wang X; Xu Z
Curr Top Med Chem; 2020; 20(16):1461-1467. PubMed ID: 31994464
[TBL] [Abstract][Full Text] [Related]
4. Benzimidazole hybrids as anticancer drugs: An updated review on anticancer properties, structure-activity relationship, and mechanisms of action (2019-2021).
Feng LS; Su WQ; Cheng JB; Xiao T; Li HZ; Chen DA; Zhang ZL
Arch Pharm (Weinheim); 2022 Jun; 355(6):e2200051. PubMed ID: 35385159
[TBL] [Abstract][Full Text] [Related]
5. Current development of pyrazole-azole hybrids with anticancer potential.
Zhang S; Ye Y; Zhang Q; Luo Y; Wang ZC; Wu YZ; Zhang XP; Yi C
Future Med Chem; 2023 Aug; 15(16):1527-1548. PubMed ID: 37610862
[TBL] [Abstract][Full Text] [Related]
6. Quinoxaline derivatives: Recent discoveries and development strategies towards anticancer agents.
Montero V; Montana M; Carré M; Vanelle P
Eur J Med Chem; 2024 May; 271():116360. PubMed ID: 38614060
[TBL] [Abstract][Full Text] [Related]
7. Current scenario of pyrazole hybrids with in vivo therapeutic potential against cancers.
Xu Z; Zhuang Y; Chen Q
Eur J Med Chem; 2023 Sep; 257():115495. PubMed ID: 37209450
[TBL] [Abstract][Full Text] [Related]
8. Current Scenario of Acridine Hybrids with Anticancer Potential.
Zhang Q; Yu X
Curr Top Med Chem; 2021; 21(19):1773-1786. PubMed ID: 34348622
[TBL] [Abstract][Full Text] [Related]
9. 1,2,3-Triazole-containing hybrids as potential anticancer agents: Current developments, action mechanisms and structure-activity relationships.
Xu Z; Zhao SJ; Liu Y
Eur J Med Chem; 2019 Dec; 183():111700. PubMed ID: 31546197
[TBL] [Abstract][Full Text] [Related]
10. Artemisinin-derived hybrids and their anticancer activity.
Gao F; Sun Z; Kong F; Xiao J
Eur J Med Chem; 2020 Feb; 188():112044. PubMed ID: 31945642
[TBL] [Abstract][Full Text] [Related]
11. Chalcone hybrids as potential anticancer agents: Current development, mechanism of action, and structure-activity relationship.
Gao F; Huang G; Xiao J
Med Res Rev; 2020 Sep; 40(5):2049-2084. PubMed ID: 32525247
[TBL] [Abstract][Full Text] [Related]
12. Coumarin-containing hybrids and their anticancer activities.
Zhang L; Xu Z
Eur J Med Chem; 2019 Nov; 181():111587. PubMed ID: 31404864
[TBL] [Abstract][Full Text] [Related]
13. Design and synthesis of quinoxaline-1,3,4-oxadiazole hybrid derivatives as potent inhibitors of the anti-apoptotic Bcl-2 protein.
Ono Y; Ninomiya M; Kaneko D; Sonawane AD; Udagawa T; Tanaka K; Nishina A; Koketsu M
Bioorg Chem; 2020 Nov; 104():104245. PubMed ID: 32911196
[TBL] [Abstract][Full Text] [Related]
14. Chemistry and pharmacological diversity of quinoxaline motifs as anticancer agents.
Ajani OO; Nlebemuo MT; Adekoya JA; Ogunniran KO; Siyanbola TO; Ajanaku CO
Acta Pharm; 2019 Jun; 69(2):177-196. PubMed ID: 31259731
[TBL] [Abstract][Full Text] [Related]
15. Ferrocene-containing hybrids as potential anticancer agents: Current developments, mechanisms of action and structure-activity relationships.
Wang R; Chen H; Yan W; Zheng M; Zhang T; Zhang Y
Eur J Med Chem; 2020 Mar; 190():112109. PubMed ID: 32032851
[TBL] [Abstract][Full Text] [Related]
16. Anticancer potential of cardiac glycosides and steroid-azole hybrids.
Hou Y; Shang C; Meng T; Lou W
Steroids; 2021 Jul; 171():108852. PubMed ID: 33887267
[TBL] [Abstract][Full Text] [Related]
17. Facile synthesis of C6-substituted benz[4,5]imidazo[1,2-a]quinoxaline derivatives and their anticancer evaluation.
Singh R; Kumar R; Pandrala M; Kaur P; Gupta S; Tailor D; Malhotra SV; Salunke DB
Arch Pharm (Weinheim); 2021 Jul; 354(7):e2000393. PubMed ID: 33749032
[TBL] [Abstract][Full Text] [Related]
18. Recent advances (2015-2016) in anticancer hybrids.
Kerru N; Singh P; Koorbanally N; Raj R; Kumar V
Eur J Med Chem; 2017 Dec; 142():179-212. PubMed ID: 28760313
[TBL] [Abstract][Full Text] [Related]
19. The current scenario on anticancer activity of artemisinin metal complexes, hybrids, and dimers.
Zhang S; Yi C; Li WW; Luo Y; Wu YZ; Ling HB
Arch Pharm (Weinheim); 2022 Aug; 355(8):e2200086. PubMed ID: 35484335
[TBL] [Abstract][Full Text] [Related]
20. Quinoxaline and quinoxaline-1,4-di-N-oxides: An emerging class of antimycobacterials.
Keri RS; Pandule SS; Budagumpi S; Nagaraja BM
Arch Pharm (Weinheim); 2018 May; 351(5):e1700325. PubMed ID: 29611626
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
